Patents by Inventor Steven Shak

Steven Shak has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 8148076
    Abstract: The present invention concerns prognostic markers associated with EGFR positive cancer. In particular, the invention concerns prognostic methods based on the molecular characterization of gene expression in paraffin-embedded, fixed tissue samples of EGFR-expressing cancer, which allow a physician to predict whether a patient is likely to respond well to treatment with an EGFR inhibitor.
    Type: Grant
    Filed: June 1, 2011
    Date of Patent: April 3, 2012
    Assignee: Genomic Health, Inc.
    Inventors: Joffre B. Baker, Maureen T. Cronin, Steven Shak, Jose Baselga
  • Publication number: 20120028264
    Abstract: Molecular assays that involve measurement of expression levels of prognostic biomarkers, or co-expressed biomarkers, from a biological sample obtained from a prostate cancer patient, and analysis of the measured expression levels to provide information concerning the likely prognosis for said patient, and likelihood that said patient will have a recurrence of prostate cancer, or to classify the tumor by likelihood of clinical outcome or TMPRSS2 fusion status, are provided herein.
    Type: Application
    Filed: July 25, 2011
    Publication date: February 2, 2012
    Inventors: Steven Shak, Frederick L. Baehner, Tara Maddala, Mark Lee, Robert J. Pelham, Wayne Cowens, Diana Cherbavaz, Michael C. Kiefer, Michael Crager, Audrey Goddard, Joffre B. Baker
  • Publication number: 20110287958
    Abstract: The invention relates to methods of determining a colorectal tumor stage in a patient by gene expression analysis. The method comprises assaying the level of at least one RNA transcript, or its expression product, which is correlated to colorectal tumor stage. The invention may be useful for determining whether a patient has stage II or stage III colorectal cancer.
    Type: Application
    Filed: May 19, 2011
    Publication date: November 24, 2011
    Inventors: Steven Shak, Margarita Lopatin, Mark Lee
  • Patent number: 8034565
    Abstract: The present invention provides gene sets the expression of which is important in the diagnosis and/or prognosis of breast cancer.
    Type: Grant
    Filed: June 4, 2009
    Date of Patent: October 11, 2011
    Assignee: Genomic Health, Inc.
    Inventors: Melody A. Cobleigh, Steven Shak, Joffre B. Baker, Maureen T. Cronin
  • Publication number: 20110178374
    Abstract: The present invention provides gene expression information useful for predicting whether a cancer patient is likely to have a beneficial response to treatment with chemotherapy, comprising measuring, in a biological sample comprising a breast tumor sample obtained from the patient, the expression levels of gene subsets to obtain a risk score associated with a likelihood of a beneficial response to chemotherapy, wherein the score comprises at least one of the following variables: (i) Recurrence Score, (ii) ESRI Group Score; (iii) Invasion Group Score; (iv) Proliferation Group Score; and (v) the expression level of the RNA transcript of at least one of MYBL2 and SCUBE2, or the corresponding expression product. The invention further comprises a molecular assay-based algorithm to calculate the likelihood that the patient will have a beneficial response to chemotherapy based on the risk score.
    Type: Application
    Filed: March 16, 2011
    Publication date: July 21, 2011
    Inventors: JOFFRE B. BAKER, JOHN L. BRYANT, SOONMYUNG PAIK, STEVEN SHAK
  • Publication number: 20110171633
    Abstract: The present disclosure provides gene and gene sets, the expression of which is important in the classification and/or prognosis of cancer, in particular of renal cell carcinoma.
    Type: Application
    Filed: January 7, 2011
    Publication date: July 14, 2011
    Inventors: Wayne Cowens, Steven Shak, Audrey Goddard, Dejan Knezevic, Joffre B. Baker, Michael C. Kiefer, Tara Maddala, Frederick L. Baehner
  • Publication number: 20110171641
    Abstract: The present invention relates to genes, the expression levels of which are correlated with likelihood of breast cancer recurrence in patients after tumor resection and chemotherapy.
    Type: Application
    Filed: October 7, 2010
    Publication date: July 14, 2011
    Inventors: JOFFRE BAKER, ROBERT GRAY, STEVEN SHAK, JOSEPH SPARANO, CARL YOSHIZAWA
  • Publication number: 20110129833
    Abstract: The present invention provides sets of genes the expression of which is important in the prognosis of cancer. In particular, the invention provides gene expression information useful for predicting whether cancer patients are likely to have a beneficial treatment response to chemotherapy. FHIT; MTA1; ErbB4; FUS; BBC3; IGF1R; CD9; TP53BP1; MUC1; IGFBP5; rhoC; RALBP1; STAT3; ERK1; SGCB; DHPS; MGMT; CRIP2; ErbB3; RAP1GDS1; CCND1; PRKCD; Hepsin; AK055699; ZNF38; SEMA3F; COL1A1; BAG1; AKT1; COL1A2; Wnt.5a; PTPD1; RAB6C; GSTM1, BCL2, ESR1; or the corresponding expression product, is determined, said report includes a prediction that said subject has a decreased likelihood of response to chemotherapy.
    Type: Application
    Filed: November 8, 2010
    Publication date: June 2, 2011
    Inventors: Joffre B. Baker, Steven Shak, Luca Gianni
  • Patent number: 7939261
    Abstract: The present invention provides a noninvasive, quantitative test for prognosis determination in cancer patients. The test relies on measurements of the tumor levels of certain messenger RNAs (mRNAs). These mRNA levels are inserted into a polynomial formula (algorithm) that yields a numerical recurrence score, which indicates recurrence risk.
    Type: Grant
    Filed: March 18, 2009
    Date of Patent: May 10, 2011
    Assignees: Genomic Health, Inc., NSABP Foundation, Inc.
    Inventors: Joffre B. Baker, John L. Bryant, Soonmyung Paik, Steven Shak
  • Patent number: 7930104
    Abstract: The present invention provides gene expression information useful for predicting whether a cancer patient is likely to have a beneficial response to treatment with chemotherapy, comprising measuring, in a biological sample comprising a breast tumor sample obtained from the patient, the expression levels of gene subsets to obtain a risk score associated with a likelihood of a beneficial response to chemotherapy, wherein the score comprises at least one of the following variables: (i) Recurrence Score, (ii) ESRI Group Score; (iii) Invasion Group Score; (iv) Proliferation Group Score; and (v) the expression level of the RNA transcript of at least one of MYBL2 and SCUBE2, or the corresponding expression product. The invention further comprises a molecular assay-based algorithm to calculate the likelihood that the patient will have a beneficial response to chemotherapy based on the risk score.
    Type: Grant
    Filed: November 4, 2005
    Date of Patent: April 19, 2011
    Assignees: Genomic Health, Inc., NSABP Foundation, Inc.
    Inventors: Joffre B. Baker, John L. Bryant, Soonmyung Paik, Steven Shak
  • Patent number: 7892549
    Abstract: The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer overexpressing ErbB2 with a combination of an anti-ErbB2 antibody and a chemotherapeutic agent other than an anthracycline, e.g. doxorubicin or epirubicin.
    Type: Grant
    Filed: February 3, 2003
    Date of Patent: February 22, 2011
    Assignee: Genentech, Inc.
    Inventors: Virginia E. Paton, Steven Shak, Susan D. Hellmann
  • Patent number: 7871769
    Abstract: The present invention provides sets of genes the expression of which is important in the prognosis of cancer. In particular, the invention provides gene expression information useful for predicting whether cancer patients are likely to have a beneficial treatment response to chemotherapy FHIT; MTA1; ErbB4; FUS; BBC3; IGF1R; CD9; TP53BP1; MUC1; IGFBP5; rhoC; RALBP1; STAT3; ERK1; SGCB; DHPS; MGMT; CRIP2; ErbB3; RAP1GDS1; CCND1; PRKCD; Hepsin; AK055699; ZNF38; SEMA3F; COL1A1; BAG1; AKT1; COL1A2; Wnt.5a; PTPD1; RAB6C; GSTM1, BCL2, ESR1; or the corresponding expression product, is determined, said report includes a prediction that said subject has a decreased likelihood of response to chemotherapy.
    Type: Grant
    Filed: April 7, 2005
    Date of Patent: January 18, 2011
    Assignees: Genomic Health, Inc., Instituto Nazionale Tumori
    Inventors: Joffre B. Baker, Steven Shak, Luca Gianni
  • Publication number: 20100285980
    Abstract: Algorithm-based molecular assays that involve measurement of expression levels of prognostic and/or predictive genes, or co-expressed genes thereof, from a biological sample obtained from a cancer patient, and analysis of the measured expression levels to provide information concerning the likelihood of recurrence of colorectal cancer and/or the likelihood of a beneficial response to chemotherapy for the patient are provided herein. Methods of analysis of gene expression values of prognostic and/or predictive genes, as well as methods of identifying gene expression-tumor region ratios, tumor-associated stromal surface area, and gene cliques, i.e. genes that co-express with a validated biomarker and thus may be substituted for that biomarker in an assay, are also provided.
    Type: Application
    Filed: April 30, 2010
    Publication date: November 11, 2010
    Inventors: Steven Shak, Drew Watson, Xitong Li, Lawrence Lee, Kim Langone
  • Publication number: 20100267032
    Abstract: The present invention provides gene sets the expression of which is important in the diagnosis and/or prognosis of cancer, in particular of breast cancer.
    Type: Application
    Filed: February 17, 2010
    Publication date: October 21, 2010
    Inventors: JOFFRE B. BAKER, JOHN L. BRYANT, SOONMYUNG PAIK, STEVEN SHAK
  • Publication number: 20100184041
    Abstract: The present invention relates to quantitative molecular indicators that can guide clinical decisions in breast cancer, such as estrogen receptor (ESR1)-positive, lymph node-negative breast cancer. In particular, the invention concerns certain genes, the varied expression of which indicates the likelihood of recurrence of surgically resected breast cancer in patients who are not treated with a therapeutic agent in the adjuvant setting. In addition, the invention concerns the use of quantitative measurement of the expression of certain genes, including the ESR1 gene, that measure as a continuous variable, to determine (a) the likelihood of a beneficial response to the anti-estrogen therapeutic agent, such as tamoxifen; and (b) the potential magnitude of beneficial response to chemotherapy.
    Type: Application
    Filed: October 9, 2009
    Publication date: July 22, 2010
    Inventors: Joffre B. Baker, John L. Bryant, Soonmyung Paik, Steven Shak
  • Patent number: 7723033
    Abstract: The present invention provides gene sets, the expression of which is important in the diagnosis and/or prognosis of cancer, in particular of breast cancer.
    Type: Grant
    Filed: January 31, 2006
    Date of Patent: May 25, 2010
    Assignees: Genomic Health, Inc., NSABP Foundation, Inc.
    Inventors: Joffre B. Baker, John L. Bryant, Soonmyung Paik, Steven Shak
  • Publication number: 20090298701
    Abstract: The present invention provides methods and compositions to facilitate determining whether an EGFR-expressing cancer in an individual is an EGFR inhibitor-responsive cancer, as well as methods for determining the likelihood that a patient having an EGFR-expressing cancer will exhibit a beneficial response to an EGFR inhibitor therapy. The methods generally involve determining a normalized expression level of a gene product that correlates with EGFR inhibitor responsiveness.
    Type: Application
    Filed: May 13, 2009
    Publication date: December 3, 2009
    Inventors: Joffre B. Baker, Drew Watson, Tara Maddala, Steven Shak, David J. Mauro, Shirin K. Ford
  • Patent number: 7622251
    Abstract: The present invention relates to quantitative molecular indicators that can guide clinical decisions in breast cancer, such as estrogen receptor (ESR1)-positive, lymph node-negative breast cancer. In particular, the invention concerns certain genes, the varied expression of which indicates the likelihood of recurrence of surgically resected breast cancer in patients who are not treated with a therapeutic agent in the adjuvant setting. In addition, the invention concerns the use of quantitative measurement of the expression of certain genes, including the ESR1 gene, that measure as a continuous variable, to determine (a) the likelihood of a beneficial response to the anti-estrogen therapeutic agent, such as tamoxifen; and (b) the potential magnitude of beneficial response to chemotherapy.
    Type: Grant
    Filed: November 4, 2005
    Date of Patent: November 24, 2009
    Assignees: Genomic Health, Inc., NSABP Foundation, Inc.
    Inventors: Joffre B. Baker, John L. Bryant, Soonmyung Paik, Steven Shak
  • Publication number: 20090280490
    Abstract: The present invention provides a noninvasive, quantitative test for prognosis determination in cancer patients. The test relies on measurements of the tumor levels of certain messenger RNAs (mRNAs). These mRNA levels are inserted into a polynomial formula (algorithm) that yields a numerical recurrence score, which indicates recurrence risk.
    Type: Application
    Filed: March 18, 2009
    Publication date: November 12, 2009
    Inventors: Joffre B. Baker, John L. Bryant, Soonmyung Paik, Steven Shak
  • Publication number: 20090125247
    Abstract: The present invention relates to genes, the expression levels of which are correlated with likelihood of breast cancer recurrence in patients after tumor resection and chemotherapy.
    Type: Application
    Filed: August 15, 2008
    Publication date: May 14, 2009
    Inventors: JOFFRE BAKER, Robert Gray, Steven Shak, Joseph Sparano, Carl Yoshizawa